ACE2 News and Research

RSS

Ablexis, AlivaMab Discovery Services, and Berkeley Lights Collaborate to Identify a Diverse Panel of Anti-SARS-CoV-2 Human Antibodies

Ablexis, LLC, ADS, and Berkeley Lights, Inc. today announced the generation and recovery of sequences against the S1 spike protein of the SARS-CoV-2 virus.

From Bruker Cellular Analysis 23 Apr 2020

Scientists identify cells likely targeted by novel coronavirus

Researchers at MIT; the Ragon Institute of MGH, MIT, and Harvard; and the Broad Institute of MIT and Harvard; along with colleagues from around the world have identified specific types of cells that appear to be targets of the coronavirus that is causing the Covid-19 pandemic.

22 Apr 2020

COVID-19 unlikely to be transmitted through semen, study shows

COVID-19 is unlikely to be spread through semen, according to University of Utah Health scientists who participated in an international study of Chinese men who recently had the disease.

22 Apr 2020

Research offers clues to how SARS-CoV-2 gets into respiratory tissue and exploits our defenses

What makes SARS-CoV-2, the virus behind COVID-19, such a threat? A new study, led by Jose Ordovas-Montanes, Ph.D. at Boston Children's Hospital and Alex K. Shalek, Ph.D. at MIT, pinpoints the likely cell types the virus infects.

22 Apr 2020

Role of ACE/ARB inhibitors in the treatment of COVID-19

A new opinion piece published in the journal Circulation Research in April 2020 defends the use of antihypertensive drugs called ACE inhibitors and ARBs in patients with pandemic viral pneumonia called COVID-19.

20 Apr 2020

ACE2 receptor expression by SARS-CoV-2 across different animal species

A new report published on the preprint server bioRxiv in April 2020 reports that several species of animals can be infected with relative ease by the SARS-CoV-2 virus that is the causative agent of the currently raging COVID-19 pandemic. This casts much light on the possible natural hosts and routes of transmission of this virus.

20 Apr 2020

Mutations in novel coronavirus make it more dangerous

A new report published on the preprint server medRxiv in April 2020 reveals that the novel coronavirus SARS-CoV-2 shows the presence of new mutations acquired within infected human cases, which significantly increase its ability to cause human disease.

20 Apr 2020

ACE2-TMPRSS2 profiling indicates tissue vulnerability to SARS-CoV-2 infection

A new study published in April 2020 on the preprint server bioRxiv reports that the different levels of susceptibility of various organs to viral attack by the SARS-CoV-2 virus causing the huge pandemic of COVID-19 sweeping around the world can be predicted from the level of expression of two molecules, the ACE2 receptor, and the TMPRSS2 protein.

20 Apr 2020

Do ACE inhibitors increase SARS-CoV-2 binding to ACE2?

The COVID-19 pandemic has forced clinicians and academicians to intensive research to find evidence for many conventional therapies. A new round-up editorial published in the journal Cardiovascular Research in April 2020 summarizes the current clinical grounds for and against the use of the commonly used angiotensin axis inhibitors in patients with COVID-19.

20 Apr 2020

Novel coronavirus mutation could spell trouble for vaccine development

New research shows that the novel coronavirus is undergoing mutations that could make it challenging to develop a vaccine against. There are a few vaccine candidates that are in the making to prevent COVID-19. With a potential for mutation, the vaccines that are being developed now may not work against the emergent mutated strains worry Taiwanese and Australian researchers. The study is titled, “Analysis of the mutation dynamics of SARS-CoV-2 reveals the spread history and emergence of 2 RBD mutant with lower ACE2 binding affinity.”

19 Apr 2020

Research suggests Nelfinavir and Cepharanthine as potential anti-SARS-CoV-2 agents

A new study published in the journal bioRxiv in April 2020 reports the identification of a promising multidrug treatment against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for causing COVID-19 disease. The team predicts that this combination will prevent the virus from reproducing, hence both halting the transmission and progress of the disease.

19 Apr 2020

Delayed clearance of SARS-CoV2 may explain why men fare worse than women

Researchers at Montefiore Health System and Albert Einstein College of Medicine may have solved a mystery surrounding the novel coronavirus pandemic: Why men infected by the virus generally show more severe symptoms and are more likely than women to die from COVID-19.

17 Apr 2020

Supercomputer helps find 64 compounds as potential inhibitors of the COVID-19 protease

A new study published in Chemrxiv in April 2020 describes the identification of 64 compounds that could potentially be inhibitors of replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is causing the current COVID-19 disease pandemic. The research was carried out using a pharmacophore model of an essential viral enzyme, mining data from the Food and Drug Administration (FDA) database of conformations of approved drugs.

16 Apr 2020

Researchers design peptide inhibitors for potential COVID-19 treatments

Scientists across the globe are rushing to find inhibitors of SARS-CoV-2, the new coronavirus behind the COVID-19 pandemic.

16 Apr 2020

Anosmia (loss of smell) confirmed as a clinical feature of COVID-19

Earlier last month, the association of ear, nose, and throat (ENT) specialists in the UK issued a public statement advising patients with a sudden loss of smell or taste to get tested for COVID-19. They cited not only their own observations but those from numerous other ENT consultants the world around. A review of multiple papers on the sinus and nasal symptoms and signs related to the diagnosis of COVID-19, published in April 2020, in the journal Laryngoscope Investigative Otolaryngology, reiterates this finding.

15 Apr 2020

ACE2 genetic variants may influence coronavirus disease progression

Researchers in British Columbia have identified a set of gene variants that are likely to influence disease progression from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to COVID-19 disease.

15 Apr 2020

COVID-19 and type 2 diabetes have shared disease pathways, study finds

Individuals with diabetes are at increased risk for bacterial, parasitic and viral infections. New research published in Endocrine Reviews, a journal of the Endocrine Society, illuminates how intersections of the coronavirus infection (COVID-19) and type 2 diabetes may require new approaches in treatment for hospitalized patients.

15 Apr 2020

Translating COVID-19 into sound

News-Medical speaks to Professor Markus Buehler about his research into COVID-19 and how he has translated the SARS-CoV-2 virus into sound.

14 Apr 2020

Novel coronavirus attacks and destroys T cells, just like HIV

The immune system has many components that work together in protecting the body from foreign invaders. One of the most important types of immune cells is T lymphocytes or T cells, a type of white blood cell that acts as the core of adaptive immunity, the system that modifies the immune response to specific pathogens.

13 Apr 2020

Hypertensive patients on ACE inhibitors and angiotensin receptor blockers may have improved COVID-19 prognosis

Emerging concerns that common antihypertensive treatment approaches with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) – jointly known as renin-angiotensin-aldosterone system (RAAS) inhibitors – may exert a negative effect in COVID-19 patients are not grounded in scientific evidence, as reported by researchers in a recent review article published in Mayo Clinic Proceedings journal.

9 Apr 2020